Selecta Biosciences (NASDAQ: SELB) will release the quarterly results report for the company on Thursday, November 3, before the opening of trading on the stock market. According to projections made by market analysts, the final three months of 2018 are expected to bring in a profit of $0.01 per share for Selecta Biosciences, according to projections made by market analysts.
On Thursday, August 4, the most recent quarterly earnings report for Selecta Biosciences (NASDAQ: SELB) was made public and presented to the investing community. The company reported earnings per share for the quarter at $0.06, which is $0.09 more than the average forecast of $0.03. The revenue for the quarter came in at $39.27 million, a significant increase from the $21.45 million that analysts had predicted would be. The return on equity for the company came in at 11.30 percent, and the net margin for the company was 24.85 percent. The company reported earnings per share in the same quarter of the prior year that were equal to $0.04 in that same period. Business analysts believe that Selecta Biosciences will not make a profit per share either during the current fiscal year or during the following fiscal year. They also believe that the company will not make a profit per share during the next year.
As a result of the decrease of $0.03 in value during trading on Friday at midday, the price of NASDAQ: SELB reached $1.60. The total number of company stock shares that changed hands was 2,629, a significantly lower volume than the typical daily volume of 662,276 shares. The stock of Selecta Biosciences hit a low of $0.65 during the past 52 weeks, while it reached a high of $4.34 during that same period. The debt-to-equity ratio is currently at 0.25, the current ratio is 5.11, and the quick ratio is also 5.11. The stock’s price-to-earnings ratio is 161.50, and its beta value is 0.98. Both of these figures are impressive. At the moment, the total market value of the company’s shares is equal to 244.34 million dollars. According to the simple moving average calculated over the past 200 days, the price of the stock is currently $1.44; however, according to the simple moving average calculated over the past 50 days, the stock price is currently $1.73.
An article about Selecta Biosciences was published on the website StockNews.com on October 12, a Wednesday. They recommended that investors purchase the company’s stock, which received a “buy” rating from them, and four experts in equity research have made this recommendation to investors. In addition, Bloomberg says that the most common recommendation for Selecta Biosciences stock is to “Buy” it and that the average price target for the stock is $5.33.
In recent months, institutional investors, such as hedge funds, have either increased or decreased their stakes in the company, depending on the path they choose to take. Price T. Rowe Associates, Inc. is the parent company of Price T. Rowe Associates, Inc. During the second quarter, MD achieved a 25.7% increase in the proportion of Selecta Biosciences stock it owned. Price T. Rowe Associates, Inc. is the parent company of Price T. Rowe Associates, Inc. MD now has a total of 21,810 shares of the company’s stock, which is currently valued at $29,000 after purchasing an additional 4,464 shares during the most recent period. This amount increased MD’s stock holdings during the most recent period. In addition, Eqis Capital Management Inc. increased its ownership stake in Selecta Biosciences by almost the same amount it invested during the first three months of 2018, approximately $30,000 more than it had previously invested. In addition, beacon Pointe Advisors LLC invested approximately $33,000 in Selecta Biosciences during the first three months to bolster its existing holdings in the company. During the second quarter of the fiscal year, Prudential Financial Inc. increased the amount of Selecta Biosciences stock owned by 16.6%. During the most recent quarter, Prudential Financial Inc. made an additional purchase of 16,680 shares of company stock, bringing the total number of shares purchased to 27,000 with a value of $35,000. Lastly, but certainly not least, during the second quarter, Jane Street Group LLC increased the proportion of Selecta Biosciences owned by 196.9%. This is not to say that this is the most important thing during this period. Jane Street Group LLC is now the owner of a total of 33,390 shares in the company, having increased its holdings during the most recent quarter by purchasing an additional 22,142 shares. These shares are currently worth $44,000, which is their market value. Institutional investors hold ownership of 37.96% of the total shares in the company at present.
The clinical research and development of nanoparticle immunomodulatory drugs for treating and preventing human diseases is the primary focus of Selecta Biosciences, Inc.. This biopharmaceutical company is currently in the clinical testing phase of its operations. In addition, the company’s most important therapeutic gene therapy program, SEL-302, is currently being tested in non-clinical settings. This is done so that the current methylmalonic acidemia treatment can be improved.
Read More: Selecta Biosciences (SELB) will report third-quarter earnings on Thursday.